TY - JOUR
T1 - Hypoxia and GABA shunt activation in the pathogenesis of Alzheimer's disease
AU - Salminen, Antero
AU - Jouhten, Paula
AU - Sarajärvi, Timo
AU - Haapasalo, Annakaisa
AU - Hiltunen, Mikko
N1 - Funding Information:
This study was funded by Academy of Finland, VTR grant V16001 of Kuopio University Hospital, Sigrid Juselius Foundation, the Strategic Funding of the University of Eastern Finland (UEF-Brain), FP7, Grant Agreement no 601055, VPH Dementia Research Enabled by IT VPH-DARE@IT , and BIOMARKAPD project in the JPND programme. Dr. Paula Jouhten additionally acknowledges funding from Academy of Finland for Postdoctoral research (grant 140380). The authors thank Dr. Ewen MacDonald for checking the language of the manuscript.
Publisher Copyright:
© 2015 Elsevier Ltd. All rights reserved.
PY - 2016/1
Y1 - 2016/1
N2 - We have previously observed that the conversion of mild cognitive impairment to definitive Alzheimer's disease (AD) is associated with a significant increase in the serum level of 2,4-dihydroxybutyrate (2,4-DHBA). The metabolic generation of 2,4-DHBA is linked to the activation of the γ-aminobutyric acid (GABA) shunt, an alternative energy production pathway activated during cellular stress, when the function of Krebs cycle is compromised. The GABA shunt can be triggered by local hypoperfusion and subsequent hypoxia in AD brains caused by cerebral amyloid angiopathy. Succinic semialdehyde dehydrogenase (SSADH) is a key enzyme in the GABA shunt, converting succinic semialdehyde (SSA) into succinate, a Krebs cycle intermediate. A deficiency of SSADH activity stimulates the conversion of SSA into γ-hydroxybutyrate (GHB), an alternative route from the GABA shunt. GHB can exert not only acute neuroprotective activities but unfortunately also chronic detrimental effects which may lead to cognitive impairment. Subsequently, GHB can be metabolized to 2,4-DHBA and secreted from the brain. Thus, the activation of the GABA shunt and the generation of GHB and 2,4-DHBA can have an important role in the early phase of AD pathogenesis.
AB - We have previously observed that the conversion of mild cognitive impairment to definitive Alzheimer's disease (AD) is associated with a significant increase in the serum level of 2,4-dihydroxybutyrate (2,4-DHBA). The metabolic generation of 2,4-DHBA is linked to the activation of the γ-aminobutyric acid (GABA) shunt, an alternative energy production pathway activated during cellular stress, when the function of Krebs cycle is compromised. The GABA shunt can be triggered by local hypoperfusion and subsequent hypoxia in AD brains caused by cerebral amyloid angiopathy. Succinic semialdehyde dehydrogenase (SSADH) is a key enzyme in the GABA shunt, converting succinic semialdehyde (SSA) into succinate, a Krebs cycle intermediate. A deficiency of SSADH activity stimulates the conversion of SSA into γ-hydroxybutyrate (GHB), an alternative route from the GABA shunt. GHB can exert not only acute neuroprotective activities but unfortunately also chronic detrimental effects which may lead to cognitive impairment. Subsequently, GHB can be metabolized to 2,4-DHBA and secreted from the brain. Thus, the activation of the GABA shunt and the generation of GHB and 2,4-DHBA can have an important role in the early phase of AD pathogenesis.
KW - Alzheimer's disease
KW - Dementia
KW - Energy metabolism
KW - GABA shunt
KW - GHB
KW - Hypoxia
UR - http://www.scopus.com/inward/record.url?scp=84954126760&partnerID=8YFLogxK
U2 - 10.1016/j.neuint.2015.11.005
DO - 10.1016/j.neuint.2015.11.005
M3 - Review Article
C2 - 26617286
AN - SCOPUS:84954126760
SN - 0197-0186
VL - 92
SP - 13
EP - 24
JO - Neurochemistry International
JF - Neurochemistry International
ER -